The posting of sponsored information and content on this page should not be considered an AAFP endorsement or recommendation of the sponsor's products, services, policies, or procedures. The information and opinions expressed on this page are those of the paid sponsors and do not necessarily reflect the view of the AAFP. The AAFP is not responsible for the content of third-party websites linked from this page; moreover, any links on this page to third-party websites where goods or services are advertised are not endorsements or recommendations by the AAFP of the third-party sites, goods, or services.
The following sponsor-developed resources may be of interest:
This monograph describes how the ANA IFA screen, in combination with reflex testing to specific autoantibody tests, may be used effectively for differential diagnosis of autoimmune diseases with one blood draw for the patient. A positive ANA IFA by itself may show pre-clinical autoimmune disease. Utilizing the ANA IFA cascade with reflex to specific antibodies can lead to early diagnosis and early treatment of potentially devastating autoimmune diseases, putting some patients in remission. Test results should be interpreted in a proper clinical context. Patient history and physical, basic chemistry panel, imaging studies, and correlation of clinical signs and symptoms with laboratory tests may help speed the time to diagnosis of complex autoimmune diseases.
Genetic tests are rapidly becoming a routine part of medical care, and informing more medical decisions than ever before. For a busy family practitioner, evaluating which tests are appropriate, when they should be used, ensuring patients are educated and informed about the tests and choosing a lab partner to run the tests are all critical to incorporating cutting-edge genetic tests into your practice.
Most women have healthy pregnancies, but about 1 in 150 pregnancies have chromosome abnormalities. Noninvasive prenatal screening (NIPS), the latest and greatest screening test for pregnant women, can identify extra or missing chromosomes in a pregnancy by analyzing cell-free DNA (cfDNA) freely floating in the maternal blood. While NIPS is a highly accurate screening tool, it is still screening. We provide details that clarify screening limitations and offer resources to help ensure patients accurately understand their results.
Autoimmune rheumatic diseases (ARDs) are diseases in which the immune system attacks the joints and certain systems. The cause of many of these diseases is unknown. ARDs are sometimes difficult to distinguish due to overlapping signs and symptoms: joint pain, diminished joint mobility, rash, fever, malaise, fatigue, and weight loss. Laboratory testing may be useful for the differential diagnosis and classification. This Clinical Focus provides background on the available laboratory tests and their use in diagnosis and classification.
www.getEPCS.com is an educational website designed to make it easy for doctors to understand what they need to do to get Electronic Prescribing of Controlled Substances (EPCS) for their practice. Although provided and supported by Surescripts, the content of the short videos and resources was developed with industry experts to be neutral, credible and shareable. The getEPCS.com website includes a self-contained Content Capsule™ that can be embedded in other websites with just a few clicks.
A detail aid that discusses the links between travel and dehydration.
There is an opportunity for integrated Clinical Decision Support (CDS) to make a profound difference in the utility of EHRs and their ability to improve quality of care. If CDS accessed patient data to help provide evidence-based recommendations at the point-of-care, they could truly improve both quality of care and outcomes.
The U.S. Preventive Task Force recommends primary care providers screen women who have family members with breast, ovarian, tubal, or peritoneal cancer with one of several screening tools designed to identify a family history that may be associated with an increased risk for potentially harmful mutations in breast cancer susceptibility genes (BRCA1 or BRCA2). Women with positive screening results should receive genetic counseling and, if indicated after counseling, BRCA testing. Screening patients with a written or electronic Family History Questionnaire (FHQ) is the first step in hereditary cancer risk assessment. A family history questionnaire will also help determine which patients are appropriate for hereditary cancer testing. For more information on how to implement a Hereditary Cancer Screening Protocol in your office, watch the following video.
The U.S. Preventive Task Force recommends that women who have a personal and/or family history of breast or ovarian cancers be screened to determine if they are at higher risk for potentially harmful genetic mutations. This video, featuring certified genetic counselor Shelly Weiss, can help you educate your patients on what they need to know about hereditary cancer.
List of Alzheimer’s resources that physicians can provide to caregivers of patients with Alzheimer’s disease